Mechanism
Incretin effects on the liver (MASLD/MASH)
Excess fat in the liver — MASLD / MASH — is closely tied to obesity and insulin resistance. Incretin therapy reduces liver fat, mainly through weight loss for GLP-1 mono-agonists; glucagon-receptor-containing combinations may add direct hepatic effects.
Plain-English explanation
Excess fat in the liver — MASLD / MASH — is closely tied to obesity and insulin resistance. Incretin therapy reduces liver fat, mainly through weight loss for GLP-1 mono-agonists; glucagon-receptor-containing combinations may add direct hepatic effects.
Research-level explanation
MRI-PDFF substudies and histology-endpoint trials are increasingly common. Resmetirom (a non-peptide thyromimetic) is the first US-licensed MASH therapy; incretin programmes are progressing through dedicated MASLD/MASH trials.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| Reducing liver fat on MRI equals curing MASH. | MRI-PDFF tracks fat content but not the inflammation or fibrosis that defines MASH histologically. Outcome trials use histology endpoints. |
Safety relevance
Hepatic safety monitoring within established product information.
- Fat-content reduction does not equal fibrosis improvement.
- Phase 2 hepatic data require phase 3 histology endpoints for regulatory and clinical confirmation.
Related peptide profiles
Related trials
Related conditions
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationLoomba R et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med 2024.
- Peer-reviewed publicationJastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med 2023.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site